Exo Therapeutics

Executive Summary

Exo Therapeutics is a preclinical-stage biotechnology company pioneering a novel approach to drug discovery by targeting exosites—regulatory binding pockets distinct from active sites—on enzymes. Leveraging its proprietary ExoSight™ platform, the company aims to modulate enzyme activity with high precision and potency, thereby expanding the druggable proteome. Exo focuses on intractable targets in oncology and inflammation, addressing significant unmet medical needs. Founded in 2017 and headquartered in Cambridge, Massachusetts, the company is privately held and has not disclosed specific financing details or pipeline programs. Exo's exosite-directed strategy could unlock new therapeutic opportunities for diseases where conventional active-site inhibitors have failed due to selectivity or resistance issues. While still in early development, the company is expected to advance its lead programs toward IND-enabling studies within the next 12–18 months. A successful Series B or C financing round would validate its platform and enable further pipeline expansion. Key upcoming milestones include preclinical data readouts and potential partnership discussions. If successful, Exo's approach could revolutionize enzyme-targeted therapies in high-need areas.

Upcoming Catalysts (preview)

• Q3 2026Series B Financing Round80% success
• Q4 2026IND Filing for Lead Program60% success
• Q2 2026Preclinical Data Presentation at Major Conference90% success